论文部分内容阅读
原发性肝癌(PHC)是常见的恶性肿瘤之一,早期不易发现,晚期的治疗效果较差,病死率很高。因此,早发现、早诊断、早治疗就成为延长患者生存期、降低病死率的关键。甲胎蛋白(AFP)是诊断PHC公认的肿瘤标志物,但存在较高的假阴性,为弥补其实验室诊断的不足、提高PHC的检出率,高尔基体蛋白73、DLC-1基因、α-L-岩藻糖苷酶、米托蒽醌抗性基因、磷脂酰肌醇蛋白多糖3和转化生长因子β1等特异性、敏感性更高的肿瘤标志物已逐渐被应用于临床。
Primary liver cancer (PHC) is one of the common malignant tumors, not easy to find early, late treatment less effective, high mortality. Therefore, early detection, early diagnosis, early treatment has become the key to prolong survival and reduce mortality. Alpha-fetoprotein (AFP) is a well-recognized tumor marker of PHC, but it has a high false-negative rate. To make up for the deficiency of its laboratory diagnosis and improve the detection rate of PHC, AFP73, DLC- Specific and sensitive tumor markers such as L-fucosidase, mitoxantrone resistance gene, glypican 3 and transforming growth factor β1 have gradually been used clinically.